NCT02808143View on ClinicalTrials.gov

Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 10, 2017

Primary Completion Date

May 15, 2020

Study Completion Date

August 5, 2022

Conditions
Recurrent Bladder CarcinomaStage 0a Bladder Urothelial CarcinomaStage 0is Bladder Urothelial CarcinomaStage I Bladder Cancer
Interventions
BIOLOGICAL

BCG Solution

Given intravesically

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given intravesically

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

60611

Northwestern University, Chicago

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER

NCT02808143 - Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter